AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice

Cell Reports

Volumn 17, Issue 5, 2016, Pages 1318-1329

  Goettel, Jeremy A ^a,b   Gandhi, Roopali ^c,d   Kenison, Jessica E ^c,d   Yeste, Ada ^c,d   Murugaiyan, Gopal ^c,d   Sambanthamoorthy, Sharmila ^c,d   Griffith, Alexandra E ^a   Patel, Bonny ^c,d   Shouval, Dror S ^a,b   Weiner, Howard L ^c,d   Snapper, Scott B ^a,b,c   Quintana, Francisco J ^c,d,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

AHR; humanized mice; IBD; ITE; treg

Indexed keywords

2 (1'H INDOLE 3' CARBONYL)THIAZOLE 4 CARBOXYLIC ACID METHYL ESTER; ANTIINFLAMMATORY AGENT; AROMATIC HYDROCARBON RECEPTOR; CARBOXYLIC ACID DERIVATIVE; CD39 ANTIGEN; GRANZYME B; INTERLEUKIN 10; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; THIAZOLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; ANIMAL; COLITIS; DISEASE MODEL; IMMUNOLOGY; METABOLISM;

ANIMALS; COLITIS; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MICE; RECEPTORS, ARYL HYDROCARBON; T-LYMPHOCYTES, REGULATORY; THIAZOLES; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID;

EID: 84994713281     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.09.082     Document Type: Article

References (72)

1. Apetoh, L., Quintana, F.J., Pot, C., Joller, N., Xiao, S., Kumar, D., Burns, E.J., Sherr, D.H., Weiner, H.L., Kuchroo, V.K., The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11 (2010), 854–861.
2. Arsenescu, R., Arsenescu, V., Zhong, J., Nasser, M., Melinte, R., Dingle, R.W., Swanson, H., de Villiers, W.J., Role of the xenobiotic receptor in inflammatory bowel disease. Inflamm. Bowel Dis. 17 (2011), 1149–1162.
3. Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500 (2013), 232–236.
4. Beaugerie, L., Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. Gut 61 (2012), 476–483.
5. Ben-Horin, S., Kopylov, U., Chowers, Y., Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 13 (2014), 24–30.
6. Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson, P.J., Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., Ochs, H.D., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27 (2001), 20–21.
7. Benson, J.M., Shepherd, D.M., Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn's disease. Toxicol. Sci. 120 (2011), 68–78.
8. Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M.L., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110 (2007), 1225–1232.
9. Burnet, F.M., Holmes, M.C., Immunological function of thymus and bursa of Fabricius. Thymus lesions in an auto-immune disease of mice. Nature 194 (1962), 146–147.
10. Calabrese, L., The yin and yang of tumor necrosis factor inhibitors. Cleve. Clin. J. Med. 73 (2006), 251–256.
11. Canavan, J.B., Scottà, C., Vossenkämper, A., Goldberg, R., Elder, M.J., Shoval, I., Marks, E., Stolarczyk, E., Lo, J.W., Powell, N., et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut 65 (2016), 584–594.
12. Chatenoud, L., Biotherapies targeting T and B cells: from immune suppression to immune tolerance. Curr. Opin. Pharmacol. 23 (2015), 92–97.
13. Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., Wahl, S.M., Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (2003), 1875–1886.
14. Chinen, I., Nakahama, T., Kimura, A., Nguyen, N.T., Takemori, H., Kumagai, A., Kayama, H., Takeda, K., Lee, S., Hanieh, H., et al. The aryl hydrocarbon receptor/microRNA-212/132 axis in T cells regulates IL-10 production to maintain intestinal homeostasis. Int. Immunol. 27 (2015), 405–415.
15. Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.F., Enjyoji, K., Linden, J., Oukka, M., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204 (2007), 1257–1265.
16. Desreumaux, P., Foussat, A., Allez, M., Beaugerie, L., Hebuterne, X., Bouhnik, Y., Nachury, M., Brun, V., Bastian, H., Belmonte, N., et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology, 143, 2012 1207–1217.e1–2.
17. Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhart, A.H., Abraham, C., Regueiro, M., Griffiths, A., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006), 1461–1463.
18. Esser, C., Rannug, A., The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol. Rev. 67 (2015), 259–279.
19. Evans, H.G., Roostalu, U., Walter, G.J., Gullick, N.J., Frederiksen, K.S., Roberts, C.A., Sumner, J., Baeten, D.L., Gerwien, J.G., Cope, A.P., et al. TNF-α blockade induces IL-10 expression in human CD4+ T cells. Nat. Commun., 5, 2014, 3199.
20. Fischer, A., Zundler, S., Atreya, R., Rath, T., Voskens, C., Hirschmann, S., López-Posadas, R., Watson, A., Becker, C., Schuler, G., et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 65 (2016), 1642–1664.
21. Fukumoto, S., Toshimitsu, T., Matsuoka, S., Maruyama, A., Oh-Oka, K., Takamura, T., Nakamura, Y., Ishimaru, K., Fujii-Kuriyama, Y., Ikegami, S., et al. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. Immunol. Cell Biol. 92 (2014), 460–465.
22. Furumatsu, K., Nishiumi, S., Kawano, Y., Ooi, M., Yoshie, T., Shiomi, Y., Kutsumi, H., Ashida, H., Fujii-Kuriyama, Y., Azuma, T., Yoshida, M., A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig. Dis. Sci. 56 (2011), 2532–2544.
23. Gandhi, R., Kumar, D., Burns, E.J., Nadeau, M., Dake, B., Laroni, A., Kozoriz, D., Weiner, H.L., Quintana, F.J., Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat. Immunol. 11 (2010), 846–853.
24. Glocker, E.O., Kotlarz, D., Boztug, K., Gertz, E.M., Schäffer, A.A., Noyan, F., Perro, M., Diestelhorst, J., Allroth, A., Murugan, D., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361 (2009), 2033–2045.
25. Goettel, J.A., Biswas, S., Lexmond, W.S., Yeste, A., Passerini, L., Patel, B., Yang, S., Sun, J., Ouahed, J., Shouval, D.S., et al. Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood 125 (2015), 3886–3895.
26. Grossman, W.J., Verbsky, J.W., Barchet, W., Colonna, M., Atkinson, J.P., Ley, T.J., Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004), 589–601.
27. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J.E., Roncarolo, M.G., A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997), 737–742.
28. Hauet-Broere, F., Unger, W.W., Garssen, J., Hoijer, M.A., Kraal, G., Samsom, J.N., Functional CD25− and CD25+ mucosal regulatory T cells are induced in gut-draining lymphoid tissue within 48 h after oral antigen application. Eur. J. Immunol. 33 (2003), 2801–2810.
29. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (2014), 40–51.
30. Hollenbach, E., Vieth, M., Roessner, A., Neumann, M., Malfertheiner, P., Naumann, M., Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J. Biol. Chem. 280 (2005), 14981–14988.
31. Huang, Z., Jiang, Y., Yang, Y., Shao, J., Sun, X., Chen, J., Dong, L., Zhang, J., 3,3′-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction. Mol. Immunol. 53 (2013), 335–344.
32. Ji, T., Xu, C., Sun, L., Yu, M., Peng, K., Qiu, Y., Xiao, W., Yang, H., Aryl hydrocarbon receptor activation down-regulates IL-7 and reduces inflammation in a mouse model of mouse model. Dig. Dis. Sci. 60 (2015), 1958–1966.
33. Josefowicz, S.Z., Lu, L.F., Rudensky, A.Y., Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30 (2012), 531–564.
34. Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., et al., International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
35. Kerkvliet, N.I., Steppan, L.B., Vorachek, W., Oda, S., Farrer, D., Wong, C.P., Pham, D., Mourich, D.V., Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 1 (2009), 539–547.
36. Khor, B., Gardet, A., Xavier, R.J., Genetics and pathogenesis of inflammatory bowel disease. Nature 474 (2011), 307–317.
37. Koreth, J., Matsuoka, K., Kim, H.T., McDonough, S.M., Bindra, B., Alyea, E.P. 3rd, Armand, P., Cutler, C., Ho, V.T., Treister, N.S., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365 (2011), 2055–2066.
38. Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., Müller, W., Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993), 263–274.
39. Le Douarin, N., Corbel, C., Bandeira, A., Thomas-Vaslin, V., Modigliani, Y., Coutinho, A., Salaün, J., Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells. Immunol. Rev. 149 (1996), 35–53.
40. Mascanfroni, I.D., Takenaka, M.C., Yeste, A., Patel, B., Wu, Y., Kenison, J.E., Siddiqui, S., Basso, A.S., Otterbein, L.E., Pardoll, D.M., et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 21 (2015), 638–646.
41. Mayne, C.G., Williams, C.B., Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm. Bowel Dis. 19 (2013), 1772–1788.
42. Miller, J.F., Immunological function of the thymus. Lancet 2 (1961), 748–749.
43. Moncrieffe, H., Nistala, K., Kamhieh, Y., Evans, J., Eddaoudi, A., Eaton, S., Wedderburn, L.R., High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J. Immunol. 185 (2010), 134–143.
44. Monteleone, I., Rizzo, A., Sarra, M., Sica, G., Sileri, P., Biancone, L., MacDonald, T.T., Pallone, F., Monteleone, G., Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 141 (2011), 237–248, 248.e1.
45. Neurath, M.F., Fuss, I., Kelsall, B.L., Stüber, E., Strober, W., Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182 (1995), 1281–1290.
46. Neurath, M.F., Fuss, I., Pasparakis, M., Alexopoulou, L., Haralambous, S., Meyer zum Büschenfelde, K.H., Strober, W., Kollias, G., Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27 (1997), 1743–1750.
47. Persidis, A., Autoimmune disease drug discovery. Nat. Biotechnol., 17, 1999, 1038.
48. Qiu, J., Guo, X., Chen, Z.M., He, L., Sonnenberg, G.F., Artis, D., Fu, Y.X., Zhou, L., Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39 (2013), 386–399.
49. Quintana, F.J., Basso, A.S., Iglesias, A.H., Korn, T., Farez, M.F., Bettelli, E., Caccamo, M., Oukka, M., Weiner, H.L., Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453 (2008), 65–71.
50. Quintana, F.J., Murugaiyan, G., Farez, M.F., Mitsdoerffer, M., Tukpah, A.M., Burns, E.J., Weiner, H.L., An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 107 (2010), 20768–20773.
51. Quintana, F.J., Jin, H., Burns, E.J., Nadeau, M., Yeste, A., Kumar, D., Rangachari, M., Zhu, C., Xiao, S., Seavitt, J., et al. Aiolos promotes TH17 differentiation by directly silencing IL2 expression. Nat. Immunol. 13 (2012), 770–777.
52. Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S.V., Teichmann, L.L., Saito, Y., Marches, F., Halene, S., Palucka, A.K., et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32 (2014), 364–372.
53. Rubtsov, Y.P., Rudensky, A.Y., TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 7 (2007), 443–453.
54. Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., Klatzmann, D., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365 (2011), 2067–2077.
55. Sakaguchi, S., Miyara, M., Costantino, C.M., Hafler, D.A., FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10 (2010), 490–500.
56. Sarin, R., Wu, X., Abraham, C., Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc. Natl. Acad. Sci. USA 108 (2011), 9560–9565.
57. Scheiffele, F., Fuss, I.J., Induction of TNBS colitis in mice. Curr. Protoc. Immunol., 49, 2002 15.19.1–15.19.14.
58. Shultz, L.D., Lyons, B.L., Burzenski, L.M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S.D., King, M., Mangada, J., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174 (2005), 6477–6489.
59. Singh, N.P., Singh, U.P., Singh, B., Price, R.L., Nagarkatti, M., Nagarkatti, P.S., Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS ONE, 6, 2011, e23522.
60. Song, J., Clagett-Dame, M., Peterson, R.E., Hahn, M.E., Westler, W.M., Sicinski, R.R., DeLuca, H.F., A ligand for the aryl hydrocarbon receptor isolated from lung. Proc. Natl. Acad. Sci. USA 99 (2002), 14694–14699.
61. Sonnenberg, G.F., Fouser, L.A., Artis, D., Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12 (2011), 383–390.
62. Takamura, T., Harama, D., Matsuoka, S., Shimokawa, N., Nakamura, Y., Okumura, K., Ogawa, H., Kitamura, M., Nakao, A., Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice. Immunol. Cell Biol. 88 (2010), 685–689.
63. Takamura, T., Harama, D., Fukumoto, S., Nakamura, Y., Shimokawa, N., Ishimaru, K., Ikegami, S., Makino, S., Kitamura, M., Nakao, A., Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. Immunol. Cell Biol. 89 (2011), 817–822.
64. Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.C., Lanzavecchia, A., Manz, M.G., Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304 (2004), 104–107.
65. Tran, D.Q., Ramsey, H., Shevach, E.M., Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110 (2007), 2983–2990.
66. Veldhoen, M., Hirota, K., Westendorf, A.M., Buer, J., Dumoutier, L., Renauld, J.C., Stockinger, B., The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453 (2008), 106–109.
67. Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A., Stockinger, B., Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206 (2009), 43–49.
68. Vogel, C.F., Goth, S.R., Dong, B., Pessah, I.N., Matsumura, F., Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem. Biophys. Res. Commun. 375 (2008), 331–335.
69. Wu, H.Y., Quintana, F.J., da Cunha, A.P., Dake, B.T., Koeglsperger, T., Starossom, S.C., Weiner, H.L., In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS ONE, 6, 2011, e23618.
70. Yeste, A., Nadeau, M., Burns, E.J., Weiner, H.L., Quintana, F.J., Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 109 (2012), 11270–11275.
71. Yeste, A., Mascanfroni, I.D., Nadeau, M., Burns, E.J., Tukpah, A.M., Santiago, A., Wu, C., Patel, B., Kumar, D., Quintana, F.J., IL-21 induces IL-22 production in CD4+ T cells. Nat. Commun., 5, 2014, 3753.
72. Zhang, L., Ma, J., Takeuchi, M., Usui, Y., Hattori, T., Okunuki, Y., Yamakawa, N., Kezuka, T., Kuroda, M., Goto, H., Activation of aryl hydrocarbon receptor suppresses experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells. Invest. Ophthalmol. Vis. Sci. 51 (2009), 2109–2117.